C'mon General Maza, lets get this Dog & Pony Show on the road. A Specialist Contract Research Organization & Leading AD Investigator. Ok, lets get them on board and lets MOVE.
"We have developed a detailed plan and time-line to corroborate these preliminary findings in additional models. We believe these additional studies are necessary to prove that TauC3 functions better than competing molecules. This work will be outsourced to specialist contract research organizations and will involve collaboration with a leading AD investigator who has developed models that are particularly well suited to test the TauC3 antibody."
I don't know, this paragraph about Conjumab seems vague & ambiguous. This really isn't a status like TAUC3 above. What the hell is going on or at a minimum the next steps with Conjumab? Did I miss it? Inquiring minds want to know...do tell ;)~
"CONJUMAB-A aims to combine a monoclonal antibody (IN-N01) targeting amyloid beta in the eye by chemically conjugating the antibody to a derivative of melatonin and thereby combining the amyloid clearing properties of the antibody with a potent antioxidant molecule. The Company purchased the original monoclonal antibody generated in mice from Immuno- Biological Laboratories (IBL) in Japan and collaborated with London-based Medical Research Council Technology (MRCT) to create a humanized form, IN-N01, which has the same properties as the original antibody."
